Patients Can Download the KetaMD Mobile App and Sign Up Anytime Through to Access Ketamine Treatment Continue Reading TORONTO, Oct. 4, 2022 /CNW/ – Braxia Scientific Corp. (“Braxia Scientific”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960) a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related…


Previous articleInterview | George Tziras, Small Pharma
Next articleMindMed Collaborators Initiate Phase 1 Comparative PK/PD Trial of R-, S- and Racemic MDMA